Perioperative Apalutamide in High-Risk Localized Prostate Cancer (Registro nro. 22813)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03511nam a2200289 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Taplin, Mary-Ellen |
| Rol del Autor | Autor |
| 9 (RLIN) | 54053 |
| 245 ## - Titulo | |
| Titulo | Perioperative Apalutamide in High-Risk Localized Prostate Cancer |
| 300 ## - Páginas | |
| Paginación | páginas: 546-560 |
| 520 ## - Resumen | |
| Resumen | Background: Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. Methods: We conducted a phase 3, double-blind, placebo-controlled trial in which patients with newly diagnosed high-risk localized or locally advanced prostate cancer were randomly assigned in a 1:1 ratio to receive androgen-deprivation therapy (ADT) plus apalutamide (240 mg per day) or ADT plus placebo for 6 cycles (28 days each) before and after radical prostatectomy with pelvic lymph-node dissection. The dual primary end points were a composite of pathological complete response or minimal residual disease (defined as a pathological stage of ypT2 or lower, with a tumor size of ≤5 mm in the greatest dimension) and metastasis-free survival, as assessed with conventional imaging or prostate-specific membrane antigen positron-emission tomography. Secondary end points included event-free survival, first subsequent treatment, and distant metastasis (assessed in time-to-event analyses), as well as safety. Results: A total of 2109 patients underwent randomization: 1057 were assigned to receive ADT plus apalutamide, and 1052 to receive ADT plus placebo. The median follow-up was 61.7 months. The percentage of patients with a pathological complete response or minimal residual disease was significantly higher in the apalutamide group than in the placebo group (8.9% vs. 1.0%; odds ratio, 10.17; 95% confidence interval [CI], 5.27 to 19.64; P<0.001), as was the percentage of patients with metastasis-free survival (probability of metastasis-free survival at 5 years, 78.2% vs. 73.5%; hazard ratio for distant metastasis or death, 0.80; 95% CI, 0.67 to 0.96; P=0.02). Event-free survival, time to the first subsequent treatment, and time to distant metastasis significantly favored ADT plus apalutamide over ADT plus placebo (P<0.001 for all between-group comparisons). Grade 3 or 4 adverse events occurred in 39.6% of the patients in the apalutamide group and in 31.0% of those in the placebo group, with the difference between the groups driven primarily by a higher incidence of rash in the apalutamide group. Conclusions: Perioperative treatment with ADT plus apalutamide was associated with better oncologic outcomes of radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer than treatment with ADT plus placebo. Adverse events were more common in the apalutamide group than in the placebo group. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CÁNCER GENITOURINARIO |
| 9 (RLIN) | 53654 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | TRATAMIENTOS EN ONCOLOGÍA |
| 9 (RLIN) | 53734 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | UROLOGÍA |
| 9 (RLIN) | 6502 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ENFERMEDADES DE LA PRÓSTATA |
| 9 (RLIN) | 53783 |
| 700 ## - Autor Personal | |
| Autor Personal | Gleave, Martin |
| 9 (RLIN) | 54054 |
| 700 ## - Autor Personal | |
| Autor Personal | Shore, Neal D. |
| 9 (RLIN) | 54055 |
| 700 ## - Autor Personal | |
| Autor Personal | Lopez-Gitlitz, Angela |
| 9 (RLIN) | 54056 |
| 700 ## - Autor Personal | |
| Autor Personal | Kretschmer, Alexander |
| 9 (RLIN) | 54057 |
| 700 ## - Autor Personal | |
| Autor Personal | Efstathiou, Eleni |
| 9 (RLIN) | 54058 |
| 700 ## - Autor Personal | |
| Autor Personal | Nguyen, Paul L. |
| 9 (RLIN) | 54059 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22644 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM009 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-08-14 |
| Catalogador | SQB |
No hay ítems disponibles.